• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health

    4/9/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email

    With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthy

    ABBOTT PARK, Ill., April 9, 2026 /PRNewswire/ -- Today, Abbott (NYSE:ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings highlighting a growing tension: 74% of U.S. adults believe most chronic diseases, such as diabetes or cardiovascular disease, are preventable, but only 1 in 4 feel very confident in knowing how to care for their health.

    In the U.S. alone, three in four American adults have at least one chronic condition1. With chronic disease continually on the rise2, Americans say they feel held back by health information overload, confusion and costs. The new research, conducted by leading marketing and analytics company, Kantar, found:

    • Sixty-five percent of people say they have delayed or avoided doing something for their health because it felt too overwhelming or expensive
    • Forty-six percent say health guidance is confusing to follow, and of those, 58% point to conflicting advice from different sources
    • And another 61% believe they should be doing more for their health

    "Healthy living shouldn't feel like a full-time job," said Dominique Williams, MD, MPH, and Nutrition Medical Director at Abbott. "The data shows people are overwhelmed and unsure how to act, but the good news is the basics still work. Simple, consistent habits around movement, nutrition and preventive care can make a difference."

    Some additional findings from the survey of 4,000 U.S. adults include:

    Generational differences add complexity

    Compared to other generations, Millennials report feeling the healthiest (65%), yet they are also the most worried. Half of millennials fear developing chronic disease if they haven't already, more than any other generation, and 58% say they could be doing more about their health.

    AI and technology in healthcare

    • Gen Z is turning to digital guidance: they are just as likely to seek health advice from AI tools as from family or friends (12%)
    • Sixty-nine percent of Gen Z respondents have used a health tracker or app in the last 12 months; Of those, 93% report a positive change in health habits, with 58% stating a lasting change – higher than other generations

    Nutrition remains a top challenge

    Ninety-six percent of Americans believe good nutrition helps prevent chronic disease, but only 30% say they personally eat "very healthy" and 42% say healthy food is too expensive.

    Parents carry unique pressure

    • Almost all parents who responded to the survey (94%) believe their children's habits today will affect their overall health as adults
    • Seventy-one percent of those surveyed worry about their children developing a chronic disease
    • Nearly 9 in 10 of those parents feel pressure to model healthy habits for their kids, yet over 40% say they aren't always modeling healthy patterns

    Abbott recently partnered with Sesame Workshop to launch a global program designed to help families everywhere create healthy routines around nutrition, movement and sleep. The program provides free, multilingual resources to help kids build healthy habits including storybooks, videos and hands‑on activities featuring beloved Sesame Street characters. Families can find and download these resources at Sesame.org/HealthyHabits.

    "As a global healthcare company that works every day to help people live healthier, we want to emphasize the simple, science-based healthy habits from daily movement, sleep and good nutrition that can help lower the risk of chronic disease," said Williams. "With many of those surveyed confused by conflicting and changing advice, it's important to trust the experts, and when it comes to your health, focus on small, attainable goals that make a real difference in long term well-being."

    Trusted guidance for chronic disease prevention

    With leading businesses in nutrition, diabetes care, cancer diagnostics and cardiovascular health, Abbott has helped prevent, diagnose, manage and treat chronic disease for more than a century.

    In addition to products and technology to help people live better, healthier lives, Abbott supports a number of community‑based programs and partnerships focused on nutrition and health access to reduce chronic disease risk and expand reach for education, care and resources. These initiatives include Future WellTM Communities, Future Well Kids, Real Madrid Foundation, Sesame Workshop, Healthy Food Rx in Stockton, California, and more.

    Join Abbott in building healthy habits

    Williams recommends simple ways to make healthy living attainable:  

    • Add nutritious foods to every meal – colorful produce, legumes, nuts
    • Move your body daily. Start with a 10‑minute walk or a 15‑minute bodyweight routine. Break activity into 5–15‑minute segments if needed
    • Schedule daily self-care to reduce overwhelm – journal, walk the dog or stretch
    • Keep track of your basics: sleep, hydration and movement
    • Maintain preventive care, including annual checkups

    Visit Abbott.com/HealthyHabits for details on how Abbott and its programs and partnerships are working to prevent chronic disease, along with the survey data and expert articles to help turn healthy intentions into daily action.

    About the study: The Abbott survey was conducted by marketing data and analytics company, Kantar, among 4,000 U.S. adults, including 2,000 parents, representing a wide range of backgrounds and geographic regions. For more details, view the fact sheet at Abbott.com/HealthyHabits.

    Abbott Chronic Disease Study, January-February 2026, 4,000 U.S. adults, Kantar

    About Kantar:

    Kantar is the world's leading marketing data and analytics business. We deliver the intelligence needed to power brand growth. We provide the signals that help organizations act quickly and confidently. We empower brands to make effective marketing decisions based on predictive evidence. And we help them craft powerful growth strategies rooted in the connection between consumers, brands and enterprise value. All this is powered by our uniquely robust human and synthetic data, our unrivalled IP, our AI-native platform and the team of global brand experts that bring this all together.

    About Abbott:

    Abbott (NYSE:ABT) is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Together with our foundation, Abbott Fund, we partner with trusted organizations to build programs that strengthen care, improve access and help families and communities thrive. We're committed to building a healthier future by inspiring lifelong habits that support well-being and help to prevent chronic disease for generations to come.

    Connect with us at Abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

    1. About Chronic Diseases | Chronic Disease | CDC. https://www.cdc.gov/chronic-disease/about/index.html

    2. Trends in Multiple Chronic Conditions Among US Adults, By Life Stage, Behavioral Risk Factor Surveillance System, 2013–2023. https://www.cdc.gov/pcd/issues/2025/24_0539.htm

     

    Cision View original content:https://www.prnewswire.com/news-releases/new-survey-finds-most-americans-believe-chronic-diseases-are-preventable-but-only-1-in-4-feel-confident-in-how-to-care-for-their-health-302737710.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    4/22/2026$92.00Outperform → Neutral
    Daiwa Securities
    10/10/2025$145.00Buy
    The Benchmark Company
    7/18/2025$145.00Hold → Buy
    Jefferies
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    More analyst ratings

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Abbott Labs downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Abbott Labs from Outperform to Neutral and set a new price target of $92.00

    4/22/26 7:52:11 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Labs upgraded by Jefferies with a new price target

    Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

    7/18/25 7:54:43 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/29/26 5:09:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/28/26 8:07:28 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)

    3 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/28/26 7:58:34 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

    First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetesIntegrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providersDesigned for compatibility with leading automated insulin delivery (AID) systemsABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with

    5/27/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

    Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guidelineAbbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based optionsRecent publications support Cologuard-first strategy, demonstrating better outcomes for patients, providers, health systems, and payersABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive scr

    5/27/26 7:01:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

    Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remissionNew MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancerEarly MCED prospective data show low anxiety and minimal psychological burden in real-world useABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago. The presentations showcase the breadth of Abbott's integrated cancer diagnost

    5/26/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $926,537 worth of Common shares without par value (10,000 units at $92.65) and was granted 2,286 units of Common shares without par value, increasing direct ownership by 0.18% to 6,751,103 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/28/26 7:37:56 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP AND CFO Boudreau Philip P bought $201,300 worth of Common shares without par value (2,200 units at $91.50) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/27/26 5:34:47 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    SEC Filings

    View All

    SEC Form SD filed by Abbott Laboratories

    SD - ABBOTT LABORATORIES (0000001800) (Filer)

    5/27/26 4:47:43 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Abbott Laboratories

    SCHEDULE 13G - ABBOTT LABORATORIES (0000001800) (Subject)

    4/29/26 4:42:23 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Abbott Laboratories

    10-Q - ABBOTT LABORATORIES (0000001800) (Filer)

    4/29/26 4:05:05 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

    Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challengesCharacter in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through Hamlin's ambassador role for the HeartMates communityMovie premieres on Hallmark Channel on Nov. 28, 2025, during Hallmark's Merry Thanksgiving Weekend during "Countdown to Christmas"ABBOTT PARK, Ill., Nov. 4,

    11/4/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABT
    Financials

    Live finance-specific insights

    View All

    Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

    First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percentCompleted acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics marketAbbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact SciencesABBOTT PARK, Ill., April 16, 2026 /PRNewswire/ -- Abbott today (NYSE:ABT) announced financial results for the first quarter ended March 31, 2026. First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.First-quarter GA

    4/16/26 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott hosts conference call for first-quarter earnings

    ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical

    3/26/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott completes acquisition of Exact Sciences

    Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segmentsAdvances Abbott's mission to make healthcare more accessible and give people more control over their healthABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. "Abbott's global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized trea

    3/23/26 8:50:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/13/24 4:55:58 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/23 10:54:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/22 3:15:56 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care